GLP‑1s reshape food menus
The surge in GLP‑1 obesity drugs is forcing major food companies to roll out high‑protein, low‑sugar offerings tailored to users—altering demand patterns for indulgent SKUs almost overnight. That change implies different price elasticity and mix effects that will show up in revenue and margin driver analyses. (en.sedaily.com)
JP Morgan models GLP‑1 effects trimming annual food-and-beverage revenue by $30 billion to $55 billion by 2030, and surveys underpinning that outlook show 70% of users report reduced snack consumption while 45% report smaller meal portions and lower alcohol intake. (en.sedaily.com) Circana projects GLP‑1 households will account for roughly 35% of U.S. food-and-beverage units sold by 2030, and some industry analysts estimate up to $12 billion in lost U.S. snack sales over the next decade—use these two published market-size estimates as alternate downside scenarios. (foodindustryexecutive.com) A household‑level consumption study found grocery spending falls by an average 5.3% within six months of starting a GLP‑1 medication, with fast‑food and coffee-shop spending down about 8% and larger declines (greater than 8%) among higher‑income households. (news.cornell.edu) Major CPG and restaurant players are already shifting assortments: PepsiCo and General Mills are investing in reformulations, while chains like Shake Shack and Chipotle and retailers M&S and Morrisons are testing smaller portions and higher‑protein, higher‑fiber SKUs. (gvwire.com) Benchmarks for driver‑based FP&A scenarios: treat current reported adoption (~10% of U.S. adults having used GLP‑1 per industry speakers) as a conservative base, model a 20% household penetration near‑term and up to Circana’s 35% units share by 2030 for stress cases. (foodtank.com) Translate micro effects into P&L levers by anchoring per‑household volume decline at Cornell’s 5.3% grocery‑spend drop, then map that to SKU‑level impacts using observed behavior (70% snack cutbacks) to reforecast mix, ASP (pack‑size downtrading), and gross margin sensitivity around higher‑protein SKUs. (news.cornell.edu) Marketing and regulatory caution: the label “GLP‑1 friendly” currently has no standardized definition, creating reputational and claims‑risk that should be modeled as potential go‑to‑market delay or rework costs when planning SKU launches and promotional investments. (hpj.com)
